4DMedical (ASX:4DX) Notes Receivable: A$0.00 Mil (As of Dec. 2025)


ASX:4DX 4DMedical Ltd ASX:4DX
64 GF Score
Price A$4.16
GF Value A$1.44
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is 4DMedical Notes Receivable?

4DMedical ASX:4DX -8.97% 64 Notes Receivable is A$0.00 Mil as of Dec. 2025. GuruFocus rates ASX:4DX with a GF Score™ of 64/100 and a GF Value™ of A$1.44 (Significantly Overvalued). The stock has 2 warning signs investors should review.

4DMedical's Notes Receivable for the quarter that ended in Dec. 2025 was A$0.00 Mil.

4DMedical Notes Receivable Historical Data

* Premium members only.

The historical data trend for 4DMedical's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4DMedical Notes Receivable Chart

4DMedical Annual Data
Trend Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Notes Receivable
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

4DMedical Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ASX:4DX
64GF Score
4DMedical Ltd ASX:4DX
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

4DMedical Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of A$0.00 Mil mean?
4DMedical (ASX:4DX) has a Notes Receivable of A$0.00 Mil as of Dec. 2025. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on 4DMedical and its competitors.
Is 4DMedical's Notes Receivable too high?
4DMedical's current Notes Receivable is A$0.00 Mil. Overall, 4DMedical has a GF Score™ of 64/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does 4DMedical's Notes Receivable compare to ABT and SYK?
4DMedical's Notes Receivable of A$0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Medical Devices & Instruments company?
A good Notes Receivable depends on the Medical Devices & Instruments industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on 4DMedical and its competitors. 4DMedical's current Notes Receivable is A$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 4DMedical stock overvalued right now?
Based on GuruFocus' analysis, 4DMedical (ASX:4DX) is currently considered Significantly Overvalued. The stock's GF Value™ is A$1.44, compared to a current price of A$4.16 — trading 188.9% above its estimated fair value. The current Notes Receivable is A$0.00 Mil. 4DMedical's overall GF Score™ is 64/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For 4DMedical (ASX:4DX), the current Notes Receivable is A$0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is 4DMedical (ASX:4DX) Overvalued in 2026?

Based on GuruFocus' analysis, 4DMedical stock appears to be overvalued. The current stock price of A$4.16 is trading 188.9% above its estimated GF Value™ of A$1.44. GuruFocus considers 4DMedical to be Significantly Overvalued.

Key valuation signals for ASX:4DX:

  • Notes Receivable: A$0.00 Mil
  • GF Value™: A$1.44 vs. price of A$4.16 (188.9% above fair value)
  • GF Score™: 64/100 with 2 warning signs

No single metric tells the full story. See the ASX:4DX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

4DMedical Business Description

Other Exchanges FDMDF:USAMQ7:Germany
Address 700 Swanston Street, Level 7, Melbourne Connect, Carlton, VIC, AUS, 3053
4DMedical Ltd is a company focused on medical research technology and the development of a non-invasive respiratory imaging solution using four-dimensional imaging. The four-dimensional lung imaging technology utilizes mathematical models and algorithms to convert X-ray scans into quantitative data, aiding physicians in managing patients with respiratory and lung diseases.
64GF Score

Get the complete analysis for ASX:4DX

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$4.16
Price
A$1.44
GF Value